Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression...

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• O(6)-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme crucial for cellular defense against alkylating agents.
• MGMT's role in cancer therapy involves modulating its expression, often lost due to MGMT promoter hypermethylation.
• Intracellular S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy) levels influence DNA and mRNA methylation, potentially regulating MGMT expression.

Purpose of the Study:

• To investigate the role of the AdoMet/AdoHcy ratio in regulating MGMT promoter methylation and mRNA expression.
• To explore the potential of modulating AdoHcy levels as a therapeutic strategy in cancer treatment.

Main Methods:

• Analysis of AdoMet/AdoHcy ratios and MGMT promoter methylation patterns in glioblastoma and hepatoma cell lines.
• Experimental manipulation of AdoMet/AdoHcy ratios using an AdoHcy hydrolase inhibitor (adenosine-2',3'-dialdehyde).
• Assessment of global DNA methylation, MGMT promoter methylation, and MGMT mRNA levels under varying AdoHcy conditions.

Main Results:

• AdoMet/AdoHcy ratios varied widely across cell lines, but were not correlated with MGMT promoter methylation or global DNA methylation under control conditions.
• Experimental elevation of AdoHcy levels, achieved by inhibiting AdoHcy hydrolase, did not alter global or MGMT promoter methylation.
• Elevated AdoHcy significantly decreased MGMT mRNA levels by over 50% in MGMT-expressing cell lines, likely due to impaired mRNA methylation.

Conclusions:

• The AdoMet/AdoHcy ratio does not appear to regulate MGMT promoter methylation.
• Elevating AdoHcy levels pharmacologically, via AdoHcy hydrolase inhibition, is a potential strategy to reduce MGMT mRNA expression.
• This approach could enhance cancer cell sensitivity to alkylating agents, improving therapeutic outcomes.